Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with advanced renal cell cancer who have already undergone prior therapy. In an early benefit assessment, the German Institute ...
Aug 10, 2016
0
0
Ospemifene (tradename: Senshio) is approved for the treatment of moderate to severe symptomatic vulvovaginal atrophy (VVA) in post-menopausal women who are not candidates for local vaginal oestrogen therapy. The drug has ...
Aug 10, 2016
0
0
At the beginning of August, the European Medicines Agency (EMA) published a report on a pilot project of a new accelerated path for drug approval (adaptive pathways). In this approval procedure, for a highly restricted population ...
Aug 9, 2016
0
0
Clinical practice guidelines can improve the quality of health care. However, the prerequisite for this is their dissemination and application. Although no best practice model for Germany is available, several requirements ...
Jul 6, 2016
0
0
If people with a diabetic foot syndrome (DFS) receive hyperbaric oxygen therapy (HBOT) in addition to conventional treatment, this can promote wound healing. However, the certainty of conclusions of the available study results ...
Jul 6, 2016
0
1
Already in 2014, the German Institute for Quality and Efficiency in Health Care (IQWiG) examined in an early benefit assessment whether idelalisib offers advantages over the appropriate comparator therapy for patients with ...
Jul 6, 2016
0
0
The monoclonal antibody necitumumab has been approved since February 2016 for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing non-small cell lung cancer (NSCLC) ...
Jul 5, 2016
0
0
The German Institute for Quality and Efficiency in Health Care (IQWiG) assessed the added benefit of ticagrelor for patients with acute coronary syndrome already in 2011 in its very first dossier assessment, just after the ...
Jul 5, 2016
0
0
Osimertinib has been approved since February 2016 for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC). ...
Jun 20, 2016
0
0
Cobimetinib (trade name: Cotellic) has been approved since November 2015 in combination with vemurafenib for the treatment of adults with advanced, i.e. metastatic or unresectable, melanoma with a BRAF V600 mutation. In a ...
Jun 3, 2016
0
2
